A Phase I Pharmacologic Study of CYC116, an Oral Aurora Kinase Inhibitor, in Patients With Advanced Solid Tumors
Clinical trial NCT00560716 · TERMINATED
Trial details
- NCT number
- NCT00560716
- Sponsor
- Cyclacel Pharmaceuticals, Inc.
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2007-06-01
- Primary completion
- 2009-01-01
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.